Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
COMPANY RESEARCH

Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell is a China-based innovative biopharmaceutical company involved in discovering, developing, manufacturing and commercializing biologic medicines. Its scientific platforms include antibody discovery and engineering, as well as antibody-drug conjugate technologies. Research areas include oncology and immune-related disease. The company's official website identifies its Shanghai and Hong Kong stock codes and describes its integrated research and production capabilities. Both stock listings belong under the same issuer identity. The company integrates antibody platform research with pharmaceutical process and manufacturing capabilities.

Publicly Listed BiopharmaOncology
My private notesAsk the research assistant ↗

Company at a glance

Corporate information

Company entity
Mabwell (Shanghai) Bioscience Co., Ltd.
Founded
Not verified
Ownership / capital status
Publicly tradedPublicly listed
LinkedIn company page
Independent company page not verified

Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.

Listed issuer and R&D focus

SSE STAR: 688062 HKEX: 02493

antibody engineering · antibody-drug conjugates

oncology · immunology

Last independently verified:

Disease tags match recorded text mentions and require program-level verification.

Technology, programs & evidence

Mabwell is a China-based innovative biopharmaceutical company involved in discovering, developing, manufacturing and commercializing biologic medicines. Its scientific platforms include antibody discovery and engineering, as well as antibody-drug conjugate technologies. Research areas include oncology and immune-related disease. The company's official website identifies its Shanghai and Hong Kong stock codes and describes its integrated research and production capabilities. Both stock listings belong under the same issuer identity. The company integrates antibody platform research with pharmaceutical process and manufacturing capabilities.

Business, technology & evidence

  • SecuritiesSSE STAR: 688062 / HKEX: 02493

Individual program detail is not recorded. Consult the original sources below.

Related news & literature

Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.

Showing 0 / 0 related items

No cataloged update explicitly mentions this company.

Same-field reading (not company-specific)

Research this company together

Discussions are for signed-in members. Personal notes remain separate from company research.

Sign in to join

Sources & open questions

    1. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·
    2. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·
    3. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·
    4. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·
    5. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·
    6. Official issuer and R&D disclosure · Mabwell (Shanghai) Bioscience Co., Ltd. ↗Mabwell (Shanghai) Bioscience Co., Ltd. ·

    Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.

    AI assistant ↗